PAVMed Is About To Enter The Commercialization Phase

  • The company has a number of products in various states of regulatory approval, each of which have a substantial market opportunity.
  • Commercialization of three of its bigger solutions is imminent and the company is in talks with various partners to speed up the development and commercialization of some of its solutions.
  • The suspension of non-essential medical procedures and clinical trials have caused some delays, but things seem to be improving already.
  • The shares remain attractive for the risk tolerant investor.

Source: PAVMed Is About To Enter The Commercialization Phase (NASDAQ:PAVM) | Seeking Alpha